Table 1.

The treatment of AD

Reference	IF	Object	Intervening measures	Results
Barry Reisberg et al. (2003)	70.67	AD	Patients with moderate‐to‐severe Alzheimer's disease were randomly assigned to receive placebo or memantine	Antiglutamatergic treatment reduced deterioration in AD
Serge Gauthier et al. (2016)	59.102	AD	Patients were randomly assigned to the experimental group and the control group to receive different doses of LMTM (a selective inhibitor of tau protein aggregation)	Gastrointestinal and urinary effects were the most common adverse events with both high doses of LMTM
Mark H Tuszynski et al. (2015)	12.321	AD	NGF gene therapy with in vitro or in vivo gene transfer in AD patients	Degenerating neurons in the AD brain responded to NGF

Note: Research on the treatment of AD in recent years.

Abbreviations: AD, Alzheimer's disease; LMTM, leuco‐methylthioninium bis; NDF, nerve growth factor.